Out Fox The $treet

Updated - Feb. 21, 2025 Hims & Hers Health isn't reliant on GLP-1 shortages. Not sure why news reports keep making this false claim, but the stock is down 20% today on the FDA ending the semagultide shortage status.  -The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs for two more months as supply conditions for the GLP-1s improve after an official end to their shortage. -Earlier in the day, the agency declared that the nationwide shortage of the highly popular GLP-1s, collectively known as semaglutide, is resolved after nearly three years. -“The FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand,” the regulator said. -Hims & Hers (NYSE:HIMS), which made compounded versions of semaglutide amid the shortage, lost billions of dollars in market cap in reaction as the telehea...

Teledoc (TDOC) is at the center of digital health. My previous research was for investors to 'pump the brakes' when the stock originally hit $60. The stock went on to surge to absurd levels reaching a high of $89. It's very crucial for investors to understand that Teledoc trading this far from the highs doesn't necessarily make the stock a bargain. The stock now trades at a market value of about $4 billion with '19 sales estimates of $550 million. Teledoc probably hits a buy zone down at $45 or when the price hits $3.3 billion or roughly 6x sales estimates. Disclosure: No position. Please review the disclaimer page for more details.